Clinical Trial

The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 18, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to assess efficacy, safety of subcutaneous SHR-1314 in pediatric patients of age 6 to \<18 years with moderate-to-Severe plaque psoriasis
Trial Details
NCT Number NCT06833307
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis
Enrollment 90 participants
Start Date 2025-02
Primary Completion 2026-07 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2025-02-18